Microbot Medical Inc (NASDAQ:MBOT) Holding Gains on IP Portfolio

Microbot Medical Inc (NASDAQ:MBOT) Holding Gains on IP Portfolio

SHARE

Microbot Medical Inc (NASDAQ:MBOT) is adding some gains to its impressive end to last week. MBOT shot up 18% after news hit the wire about its improved IP portfolio. Its endoscope technology platform was granted in India and the company seemed to rise up out of dormancy after the news.

“We continue to strengthen and expand our IP portfolio,” commented Harel Gadot, Chief Executive Officer, President, and Chairman. “As a pioneer in micro-robotic surgery, this will allow us to add value to our assets as it is expected to enhance our ability to access global markets and create additional competitive advantages and barriers to entry. India is a large and emerging market and we believe having a strong IP presence in this market further builds shareholder value.  In addition to India, the TipCAT™ technology platform patent has already been granted in the largest markets such as the U.S., China, Europe and several other markets, which we believe continues to show the strength of our IP assets.  With this specific IP, our objective is to leverage the TipCAT platform to develop multiple products that address serious unmet needs in multiple medical applications.”

Microbot Medical Inc (NASDAQ:MBOT), which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob™ and TipCAT™, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS™, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.

The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body.  Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system.  Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time.

TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract.  Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body.

Find out when $MBOT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Globally, the Company now has 23 patents which are already issued and an additional 13 patent applications pending worldwide.

Most analysts consider this stock being extremely undervalued. Some reports have even showed the stock with the potential to shoot up to the +$100 range. These reports are all speculative, of course. However, the technology platform here is strong and legitimate. Investors should be watching closely, especially if the stock continues to run upward.

Right now, Microbot Medical Inc (NASDAQ:MBOT) has a $43.16M market cap with 34.81M shares out. The stock has tumbled this year but was once worth more than $8 in 2017. It might behoove one to buy the dip, but proceed with caution.  Sign-up for continuing coverage on shares of $MBOT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: We hold no position in $MBOT, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter